INDIA – Indian Immunologicals Limited (IIL) has awarded approximately Rs 700 crores (US$84,193,550) for the construction of its new greenfield veterinary vaccine manufacturing plant in Hyderabad State.

With an investment of approximately Rs 700 crores (US$84,193,550), the proposed vaccine factory is expected to create more than 750 direct and indirect jobs.

In a press release, IIL said: “This brand-new unit will have a BSL3 facility for the manufacture of drug substances and a fill-finish capability for the production of both drug products Foot and Mouth Disease Vaccine and the Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine.”

Dr. K Anand Kumar highlighted that the Indian company is undergoing an exponential growth phase, noting that it is expected to grow by 40% over the course of the year alone.

Laying out his future plans, Dr. K Anand Kumar reflected: “In order to sustain the momentum, IIL is seriously considering making additional investments in building infrastructure within India.”

He further mentioned that the company plans to make additional investments outside India, including emerging geographies like Africa.

He explained that this funding injection will bolster its capabilities and allow IIL to develop tools that will help in the control and eradication of diseases in India and beyond.

With over 150 manufactured products, Indian Immunologicals Limited, a subsidiary of the National Dairy Development Board, is the market leader in veterinary and human biologicals in the country.

IIL’s new greenfield veterinary vaccine facility is expected to manufacture the Foot and Mouth Disease Vaccine (FMD-Vac) as well as Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine (FMD+HS-Vac) in Hyderabad’s Genome valley.

It is important to note that Indian Immunologicals Limited, which is based in Telangana, is registered in India as a Public Limited Company under the Companies Act, 1956.

During the groundbreaking ceremony for the new vaccine factory, Dr. K Anand Kumar, Managing Director of IIL, stated: “We are the largest supplier of FMD vaccine to the Government of India’s prestigious Livestock Health Disease Control Programme (LHDCP).”

Prior to the groundbreaking ceremony, the Telangana State Industrial Infrastructure Corporation Ltd (TSIIC) allotted a piece of land to IIL at Biotech Park, Phase III, Karkapatla, Siddipet District in Telangana.

IIL’s proposed vaccine manufacturing facility will have a capacity of 150 million doses/annum of FMD vaccine or FMD+HS vaccine each, according to IIL.

Over the years, IIL’s Research & Development (R&D) team has collaborated with several national and international institutes of repute in the area of vaccines. This has enabled the development of top novel products for overall well-being.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.